Aurora M. Fontainhas

Array ( [id] => 16523777 [patent_doc_number] => 20200397857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => METHODS AND COMPOSITIONS FOR PROMOTING OPC DIFFERENTIATION AND REMYELINATION USING RECEPTOR ASSOCIATED PROTEIN (RAP) [patent_app_type] => utility [patent_app_number] => 16/867058 [patent_app_country] => US [patent_app_date] => 2020-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343612 [patent_doc_number] => 20200308262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING VIRUS-ASSOCIATED INFLAMMATION [patent_app_type] => utility [patent_app_number] => 16/856407 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398780 [patent_doc_number] => 20200339638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/856774 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16533326 [patent_doc_number] => 10875910 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Antibodies recognizing alpha-synuclein [patent_app_type] => utility [patent_app_number] => 16/856855 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 17394 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16391070 [patent_doc_number] => 20200332011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease [patent_app_type] => utility [patent_app_number] => 16/852508 [patent_app_country] => US [patent_app_date] => 2020-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79106 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16852508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16397290 [patent_doc_number] => 20200338148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/846210 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34277 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16296357 [patent_doc_number] => 20200282080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/841539 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16296357 [patent_doc_number] => 20200282080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/841539 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16296357 [patent_doc_number] => 20200282080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/841539 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16296357 [patent_doc_number] => 20200282080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/841539 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621534 [patent_doc_number] => 20210040187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => NANOBODIES SUITABLE FOR NEURON REGENERATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/839009 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236879 [patent_doc_number] => 20200254113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS [patent_app_type] => utility [patent_app_number] => 16/828557 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19368517 [patent_doc_number] => 12060591 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Tau protease compositions and methods of use [patent_app_type] => utility [patent_app_number] => 16/822906 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 33 [patent_no_of_words] => 40407 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16571019 [patent_doc_number] => 20210010025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => TREATMENT OF OCULAR DISEASES WITH HUMAN POST-TRANSLATIONALLY MODIFIED VEGF-TRAP [patent_app_type] => utility [patent_app_number] => 16/810422 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17453251 [patent_doc_number] => 11268097 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability [patent_app_type] => utility [patent_app_number] => 16/808611 [patent_app_country] => US [patent_app_date] => 2020-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 8 [patent_no_of_words] => 14546 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468218 [patent_doc_number] => 20200369755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => ANTIBODIES RECOGNIZING TAU [patent_app_type] => utility [patent_app_number] => 16/808209 [patent_app_country] => US [patent_app_date] => 2020-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283760 [patent_doc_number] => 20200277362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => Humanized Antibodies That Recognize Alpha-Synuclein [patent_app_type] => utility [patent_app_number] => 16/795479 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16459 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16093563 [patent_doc_number] => 20200200768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => NOVEL BIOMARKERS FOR COGNITIVE IMPAIRMENT AND METHODS FOR DETECTING COGNITIVE IMPAIRMENT USING SUCH BIOMARKERS [patent_app_type] => utility [patent_app_number] => 16/791984 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16361024 [patent_doc_number] => 20200317775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => SP35 Antibodies And Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/789738 [patent_app_country] => US [patent_app_date] => 2020-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16789738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16650004 [patent_doc_number] => 10927167 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Anti-complement factor C1Q antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/784020 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 35321 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16784020 [rel_patent_id] =>[rel_patent_doc_number] =>)